PublicationSecondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates
In this paper MDS was used to identify two molecular chaperones which suppress secondary nucleation processes and inhibit the elongation of Aβ fibrils seen in Alzheimer's disease.
Blog5 great reads: Protein-protein interactions and disease
Here are five of our favorite recent publications, highlighting both the role of protein-protein interactions in disease and how the characterization of these interactions may allow the development of new therapeutic strategies.
Application noteRapid quality control of commercially available antibodies by MDS for acceptance testing
Size presents a simple metric to assess quality as an indicator of aggregation and degradation. Here MDS on the Fluidity One and SEC analysis are both used to check 6 commercially available antibodies. Both techniques sucessfully identify problem samples, but MDS does so with 80% less time and 90% less sample.
BlogSources of inaccuracy in protein aggregation measurement
This blog explores the points to look out for when measuring protein aggregation through a variety of techniques that can reduce the accuracy of your results.
BlogProtein aggregation - why it matters, and how to study it
A growing field of research is dedicated to protein aggregation, which can be useful, functional or unwanted. This article explores some of the reasons why proteins aggregate, and details the techniques available to study it.
BlogThe role of analytics in the discovery and development of biopharmaceuticals
As the biopharmaceuticals market continues to grow, how do laboratory analysis methods support discovery and development? And what should be considered when selecting an analysis method?
Application noteInterleukin-2 stability in changing buffer and temperature conditions
The stability of interleukin-2 in different buffers and storage temperatures is evaluated using the Fluidity One. We find that IL-2 forms aggregates within 24 hours in some buffers, and that the Fluidity One provides a simple means to evaluate the stability of proteins across different conditions.
BlogWhat biophysical attributes of biopharmaceuticals are measured, and why?
An array of characteristics must be investigated in new biopharmaceuticals to evaluate their safety, efficacy and behaviour under changing conditions. Here we look at what specific attributes should be measured and why.